PCN227 A COMPARISON BETWEEN ICER (US) AND NICE (UK) HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISION-MAKING FOR PD-1 INHIBITORS IN NON-SMALL-CELL LUNG CARCINOMA (NSCLC): OTHER BENEFITS AND CONTEXTUAL CONSIDERATIONS.
2019
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI